Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Rentsch, Cyrill A., Bosshard, Piet, Mayor, Grégoire, Rieken, Malte, Püschel, Heike, Wirth, Grégory, Cathomas, Richard, Parzmair, Gerald P., Grode, Leander, Eisele, Bernd, Sharma, Hitt, Gupta, Manish, Gairola, Sunil, Shaligram, Umesh, Goldenberger, Daniel, Spertini, François, Audran, Régine, Enoiu, Milica, Berardi, Simona, Hayoz, Stefanie, Wicki, Andreas
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2020
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185202/
https://ncbi.nlm.nih.gov/pubmed/32363120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1748981
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi